Goldman Sachs is working on plan to raise as much as €250 million in debt to fund the refurbishing of the stadium for Spanish football club Real Betis https://t.co/weid3tPcWM ...

A trio of banks joined Morgan Stanley in a $5 billion debt deal for xAI, after the company requested their participation to maintain relationships that could help with financings down the line https://t.co/AXgjWlpDZV ...

Proceeds from the offering of senior unsecured notes to be used to repay borrowings under the senior secured term loan facilitiesMIAMI, July 1, 2025 /PRNewswire/ -- Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK) today announced that Carnival plc (the "Company") priced its private offering (the "Notes Offering") of €1.0 billion aggregate principal amount of 4.125% senior unsecured notes due 2031 (the "Notes"). The Company expects to use the proceeds from the Notes Offering to fully repay the borrowing ...

SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) ("Banzai" or the "Company"), a leading marketing technology company that provides essential marketing and sales solutions, today announced the completion of an $11.0 million dollar debt facility with an institutional investor to support acquisitions and ongoing operations. The financing includes an initial tranche of $2.2 million (the "Note"), which matures on June 30, 2026, bears interest at 10% per annum, and is secured b ...

Bankers are vying to play a part in the debt financing backing Advent's potential acquisition of a suite of Reckitt Benckiser's homecare brands https://t.co/wqPbmFgfDW ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 24, 2025 (GLOBE NEWSWIRE) -- Integral Metals Corp. (CSE: INTG | FSE: ZK9) (the “Company” or “Integral”) announces that it has entered into a secured convertible debt financing transaction (the “Transaction”) with a strategic investor (“Lender”) pursuant to which it has received loan proceeds of US$1,000,000 (the “Loan”) on the terms and conditions set forth in a Loan and Security Agreeme ...

The weighted average cost of capital (WACC) calculates a company's cost of capital, proportionately weighing its use of debt and equity financing. https://t.co/hX5n8SBmwE ...

Core Viewpoint - NeuroPace, Inc. has secured a new $75 million credit facility with MidCap Financial to enhance its financial flexibility and support growth initiatives in the epilepsy treatment market [1][2]. Financing Details - The credit facility consists of a $60 million term loan and a $15 million revolving credit facility, with proceeds from the term loan used to repay an existing loan with CRG Partners IV, L.P. [1][2] - The new loan agreement has a maturity date of five years, with an annual interest rate tied to SOFR, subject to a floor of 2%, plus 5.5% for the term loan and 3.75% for the revolving loan [2]. Strategic Goals - The company aims to use the proceeds to expand patient access to its RNS System, invest in site-of-service expansion, explore new indications, develop direct-to-consumer programs, and generate real-world evidence [2]. - NeuroPace's RNS System is the first commercially available brain-responsive platform designed to provide personalized treatment for drug-resistant epilepsy [4]. Company Background - NeuroPace is based in Mountain View, California, and focuses on transforming the lives of individuals with epilepsy by reducing or eliminating seizures through innovative medical devices [4]. - The company has a unique position in the market with its differentiated RNS System, which aims to improve care standards for patients suffering from various brain disorders [4]. Partner Information - MidCap Financial specializes in providing senior debt solutions to middle-market companies and manages approximately $55 billion in commitments as of March 31, 2025 [5].

Core Viewpoint - Teva Pharmaceutical Industries Ltd. has successfully upsized its offering of senior notes to approximately $2.3 billion, increasing from a previously announced $2 billion, with proceeds intended for tender offers and debt repayment [1][3]. Group 1: Offering Details - The offering consists of €1 billion of 4.125% EUR-denominated Senior Notes maturing in 2031, $500 million of 6.000% USD-denominated Senior Notes maturing in 2032, and $700 million of 5.750% USD-denominated Senior Notes maturing in 2030 [2]. - The settlement of the notes is expected to occur on or about May 28, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund tender offers for various senior notes, pay associated fees and expenses, and repay outstanding debt upon maturity or earlier redemption [1]. Group 3: Company Background - Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader with over 120 years of commitment to health, employing 37,000 people across 57 markets to develop medicines and produce generics and biologics [6][7].

Prophase Labs (PRPH) Q1 2025 Earnings Call May 20, 2025 10:00 AM ET Company Participants Noella Alexander-Young - Media Relations Coordinator & Virtual Events ModeratorTed Karkus - Chairman & CEO Noella Alexander-Young Hello, and good morning, everyone. Welcome to today's presentation. My name is Noella Alexander Young, virtual event moderator here at Renmark Financial Communications. On behalf of our team, we want to thank everyone for joining us today for Prophase Labs First Quarter twenty twenty five Res ...